Home

HENRY J FUCHS

CIK 1197355 · President, Worldwide R&D · last filed 2024-09-17

HENRY J FUCHS is a President, Worldwide R&D who has filed 195 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for BMRN, was dated Sep 17, 2024. Across all open-market trades the lifetime net is −$76.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $11.5M across reported positions. 125 SEC filings were submitted jointly with BIOMARIN PHARMACEUTICAL INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$11.51M

Companies

5

Total Filings

195

Lifetime Open-Market Net

-$76.63M

Filer Profile

Reported Address
C/O BIOMARIN PHARMACEUTICAL INC.
105 DIGITAL DRIVE
NOVATO, CA 94949
Related Filers
BIOMARIN PHARMACEUTICAL INC — 125 joint filings, latest 2024-09-17
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
BMRN President, Worldwide R&D 185,074 $62.21 $11.51M -$62.29M 112 2024-09-17
Mirati Therapeutics, Inc. (MRTX) Delisted Director 10,465 $58.70 $614.3K -$4.81M 13 2023-01-24
GENOMIC HEALTH INC (GHDX) Delisted Director 7,833 — — -$2.45M 29 2019-10-03
Ardea Biosciences, Inc./DE (RDEA) Delisted Director 0 — — -$1.73M 20 2012-06-20
ONYX PHARMACEUTICALS INC (ONXX) Delisted EVP & Chief Medical Officer 14,891 — — -$5.36M 17 2008-11-19

Recent Filings

195 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2024-09-17 BMRN Mixed −11,798 -$1.01M EDGAR
2024-03-19 BMRN Mixed −15,245 -$2.81M EDGAR
2024-03-07 BMRN Sell (S) −35,341 -$3.01M EDGAR
2024-03-05 BMRN Notice (144) −35,341 -$3.01M EDGAR
2024-02-29 BMRN Grant (A) +53,204 $0 EDGAR
2023-12-05 BMRN Grant (A) +18,067 $21.2K EDGAR
2023-08-11 BMRN Sell (S) −12,000 -$1.09M EDGAR
2023-08-10 BMRN Notice (144) −12,000 -$1.09M EDGAR
2023-03-17 BMRN Mixed −23,959 -$3.78M EDGAR
2023-03-02 BMRN Grant (A) +68,052 $0 EDGAR
Showing 1–10 of 195
Page 1 of 20
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.